Literature DB >> 19812297

Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.

Mia Faerch1, Jane H Christensen, Søren Rittig, Jan-Ove Johansson, Niels Gregersen, Francis de Zegher, Thomas J Corydon.   

Abstract

X-linked congenital nephrogenic diabetes insipidus (CNDI) is characterized by a defective renal response to the antidiuretic hormone (AVP) due to variations in the arginine vasopressin receptor 2 (AVPR2) gene. In a unique group of patients, the renal insensitivity to the effects of AVP is incomplete resulting in a partial phenotype. To investigate the molecular defects, two previously published variations in the AVPR2 gene, known to cause a partial CNDI phenotype, were expressed in transiently transfected human embryonic kidney cells. One variation (p.Arg104Cys) is located in the first extracellular loop and the other variation (p.Ser329Arg) is located in the intracellular COOH terminal of the receptor protein. Western blotting showed almost equal amounts of WT-V2R and Arg104Cys-V2R protein at steady state, whereas the level of Ser329Arg-V2R protein was lower. Confocal microscopy established that WT-V2R and Arg104Cys-V2R are localized on the cellular surface while the Ser329Arg-V2R primarily accumulates within the endoplasmic reticulum resulting in reduced surface expression. Ligand binding analysis demonstrated that the B(max) for cells expressing Arg104Cys-V2R and Ser329Arg-V2R were 14.8- and 2.5-fold lower than B(max) for WT-V2R, respectively. AVP affinity (1/K(d)) for WT-V2R and the Ser329Arg-V2R was similar while 1/K(d) for Arg104Cys-V2R was increased. cAMP assay revealed that cells expressing p.Arg104Cys-V2R or p.Ser329Arg-V2R produced 1.7- and 6.8-fold lower amounts of cAMP compared with WT-V2R, respectively. In conclusion, ligand binding and signal transduction capability are dependent on localization of the amino acid variation. Striking divergences at the level of receptor functionality may thus underlie similar clinical phenotypes in CNDI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812297     DOI: 10.1152/ajprenal.00331.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  8 in total

1.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  A 4-year-old boy presenting with persistent urinary incontinence: Answers.

Authors:  Werner Keenswijk; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2016-06-27       Impact factor: 3.714

3.  Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus.

Authors:  Shivani Joshi; Helene Kvistgaard; Konstantinos Kamperis; Mia Færch; Søren Hagstrøm; Niels Gregersen; Søren Rittig; Jane Hvarregaard Christensen
Journal:  Eur J Pediatr       Date:  2018-03-28       Impact factor: 3.183

4.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

5.  Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.

Authors:  Noriko Makita; Tomohiko Sato; Yuki Yajima-Shoji; Junichiro Sato; Katsunori Manaka; Makiko Eda-Hashimoto; Masanori Ootaki; Naoki Matsumoto; Masaomi Nangaku; Taroh Iiri
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

6.  Personalized biochemistry and biophysics.

Authors:  Brett M Kroncke; Carlos G Vanoye; Jens Meiler; Alfred L George; Charles R Sanders
Journal:  Biochemistry       Date:  2015-04-15       Impact factor: 3.162

7.  Novel de novo AVPR2 Variant in a Patient with Congenital Nephrogenic Diabetes Insipidus.

Authors:  Shivani Joshi; Per Brandstrom; Niels Gregersen; Søren Rittig; Jane Hvarregaard Christensen
Journal:  Case Rep Nephrol Dial       Date:  2017-09-27

8.  An eEF1A1 truncation encoded by PTI-1 exerts its oncogenic effect inside the nucleus.

Authors:  Louise D Dahl; Thomas J Corydon; Liina Ränkel; Karen Margrethe Nielsen; Ernst-Martin Füchtbauer; Charlotte R Knudsen
Journal:  Cancer Cell Int       Date:  2014-02-26       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.